Enliven Therapeutics
ELVN
41.36
-1.03
-2.43%
Enliven Therapeutics
US · ELVN
#2416 by market cap
Listed 1970
41.36
-1.03
-2.43%
Live - 5344 symbols - heartbeat 80s ago
· 2026-10-08 08:20
Pre-market
43.00
+3.97%
After-hours
41.36
0.00%
Overnight
41.74
+0.92%
- Market cap
- 3.03B
- P/E (TTM)i
- -25.07
- P/Bi
- 3.39
- EPSi
- -1.83
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on ELVN?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 14 analysts
Buy
Avg price target
73.67 +78.1%
Price target rangecurrent 41.36
Low65.00
Avg73.67
High82.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | Morgan Stanley | -- | BUY | 70.00 |
| 2026-10-02 | Morgan Stanley | -- | BUY | 70.00 |
| 2026-10-01 | J.P. Morgan | -- | BUY | 75.00 |
| 2026-08-22 | William Blair | -- | BUY | -- |
| 2026-08-18 | William Blair | -- | BUY | -- |
| 2026-08-18 | Barclays | -- | BUY | 78.00 |
| 2026-08-17 | Mizuho Securities | -- | BUY | 73.00 |
| 2026-08-13 | Stifel | -- | BUY | 82.00 |
| 2026-08-08 | LifeSci Capital | -- | BUY | 70.00 |
| 2026-08-07 | LifeSci Capital | -- | BUY | 70.00 |
| 2026-08-06 | JonesTrading | -- | BUY | 70.00 |
| 2026-08-06 | Baird | -- | BUY | 75.00 |
| 2026-08-06 | Clear Street | -- | BUY | 68.00 |
| 2026-08-06 | Stifel | -- | BUY | 82.00 |
| 2026-08-05 | TD Cowen | -- | BUY | -- |
| 2026-08-05 | Goldman Sachs | -- | BUY | 80.00 |
| 2026-08-05 | Guggenheim | -- | BUY | 78.00 |
| 2026-07-20 | Goldman Sachs | -- | BUY | 67.00 |
| 2026-07-09 | H.C. Wainwright | -- | BUY | 65.00 |
| 2026-07-01 | Stifel | -- | BUY | 80.00 |
| 2026-06-29 | JonesTrading | -- | BUY | 70.00 |
| 2026-06-12 | Guggenheim | -- | BUY | 80.00 |
| 2026-06-11 | TD Cowen | -- | BUY | -- |
| 2026-06-11 | LifeSci Capital | -- | BUY | 60.00 |
| 2026-06-11 | JonesTrading | -- | BUY | 45.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 08:20:04 · For reference only, not investment advice and not tailored to your situation.